心血管领域的合作研究与授权协议（2016-2026 年）

本报告分析了心血管领域 650 多项合作研究和授权协议，清晰地、以证据为基础地阐述了整个市场伙伴关係的设计、协商和执行方式。

目录

执行摘要

第一章：引言

第二章：心血管合约的发展趋势

• 介绍
• 过去几年在心血管领域的合作
• 心血管合作项目：按合约类型划分
• 心血管合作：依产业划分
• 心血管合作：依发展阶段
• 心血管合作：依技术类型划分
• 心血管协作：依治疗指征

第三章 心血管合作的财务协议条款

• 介绍
• 已披露的心血管合作项目的财务条款和条件
• 心血管合作项目的主要金额
• 心血管合约进展
• 心血管合约的里程碑付款
• 心血管领域权利金费率

第四章：心血管领域的主要合约和承包公司

• 介绍
• 在心血管领域合作方面最积极主动的公司
• 心血管领域最活跃的承包公司名单
• 心血管领域价值排名前列的合约

第五章：心血管领域的合约记录

• 介绍
• 可提供合约的心血管合作协议

第六章：心血管收缩：依治疗标靶划分

• 介绍
• 合约：透过心血管治疗标靶
• 合约记录
• 合约记录 - 心血管合约：按公司分类 (AZ)
• 合约记录 - 心血管合约：按技术类型分类
• 合约类型的定义
• 关于 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作伙伴近期报告标题

The definitive benchmark for cardiovascular dealmaking

Cardiovascular remains one of the most active and strategically important therapeutic areas for partnering, with deal structures varying widely across indications, modalities, and stages of development.

This report provides a comprehensive and structured analysis of 650+ cardiovascular collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how cardiovascular deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within cardiovascular partnerships.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 650+ cardiovascular collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cardiovascular dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how cardiovascular partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cardiovascular dealmaking

• 2.1. Introduction
• 2.2. Cardiovascular partnering over the years
• 2.3. Cardiovascular partnering by deal type
• 2.4. Cardiovascular partnering by industry sector
• 2.5. Cardiovascular partnering by stage of development
• 2.6. Cardiovascular partnering by technology type
• 2.7. Cardiovascular partnering by therapeutic indication

Chapter 3 - Financial deal terms for cardiovascular partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for cardiovascular partnering
• 3.3. Cardiovascular partnering headline values
• 3.4. Cardiovascular deal upfront payments
• 3.5. Cardiovascular deal milestone payments
• 3.6. Cardiovascular royalty rates

Chapter 4 - Leading cardiovascular deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in cardiovascular partnering
• 4.3. List of most active dealmakers in cardiovascular
• 4.4. Top cardiovascular deals by value

Chapter 5 - Cardiovascular contract document directory

• 5.1. Introduction
• 5.2. Cardiovascular partnering deals where contract document available

Chapter 6 - Cardiovascular dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by cardiovascular therapeutic target
• Deal directory
• Deal directory - Cardiovascular deals by company A-Z
• Deal directory - Cardiovascular deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cardiovascular partnering since 2016
• Figure 2: Cardiovascular partnering by deal type since 2016
• Figure 3: Cardiovascular partnering by industry sector since 2016
• Figure 4: Cardiovascular partnering by stage of development since 2016
• Figure 5: Cardiovascular partnering by technology type since 2016
• Figure 6: Cardiovascular partnering by indication since 2016
• Figure 7: Cardiovascular deals with a headline value
• Figure 8: Cardiovascular deals with upfront payment values
• Figure 9: Cardiovascular deals with milestone payment
• Figure 10: Cardiovascular deals with royalty rates
• Figure 11: Active cardiovascular dealmaking activity since 2016
• Figure 12: Top cardiovascular deals by value since 2016